Dr. Roberts has received honoraria for speaking from Merck, Whitehouse Station, New
Jersey; Schering Plough, Kenilworth, New Jersey; Pfizer, New York, New York; AstraZeneca,
Wilmington, Delaware; and Novartis, Annandale, New Jersey. Dr. Black has received
honoraria for speaking and consulting from Pfizer, Novartis, Bristol-Myers Squibb,
New York, New York; Sanofi-Aventis, Bridgewater, New Jersey; Forest, New York, New
York; Boehringer-Ingelheim, Ridgefield, Connecticut; Merck, Gilead, Foster City, California;
Myogen, and Intercure, Fort Lee, New Jersey. Dr. Bakris has received honoraria for
speaking and consulting from AstraZeneca, Abbott, Abbott Park, Illinois; Bristol-Myers
Squibb/Sanofi-Aventis, GlaxoSmithKline, Research Triange Park, North Carolina; Merck,
Novartis, Lilly, Indianapolis, Indiana; Walgreens, and Myogen. He has received grants
from the National Institutes of Health, Abbott, Boehringer-Ingelheim, GlaxoSmithKline,
Novartis, and Myogen. Dr. Mason has received investigator-initiated research grants
and honoraria for speaking or consulting from sanofi-aventis, Bristol-Myers Squibb,
Pfizer, and Forest Laboratories. Dr. Giles has received honoraria for speaking and
consulting from Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, Novartis,
Forest Laboratories, and Pfizer. He has received grant funding from Novartis and AstraZeneca.
All other individuals in a position to control content disclosed no relevant financial
relationships.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP (JNC V).Arch Intern Med. 1993; 153: 154-183
- Medical Research Council trial of treatment of hypertension in older adults: principal results.BMJ. 1992; 304: 405-412
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BP Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.Lancet. 2005; 366: 895-906
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet. 2002; 359: 995-1003
- Should β blockers remain first choice in the treatment of primary hypertension?.Lancet. 2005; 366: 1545-1553
- The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP.JAMA. 2003; 289: 2560-2572
- Heart disease and stroke statistics–2007 update.Circulation. 2007; 115: e69-e171
- Racial disparities in hypertension prevalence, awareness, and management.Arch Intern Med. 2005; 165: 2098-2104
- Role of BP in cardiovascular disease: the Framingham Study.Angiology. 1975; 26: 1-14
- Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial.Prev Med. 1986; 15: 254-273
- Health outcomes associated with antihypertensive therapies used as first-line agents.JAMA. 1997; 277: 739-745
- Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overview of randomised trials.Lancet. 2000; 356: 1955-1964
- Age-specific relevance of usual BP to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies.Lancet. 2002; 360: 1903-1913
- Expert consensus document on β-adrenergic receptor blockers.Eur Heart J. 2004; 25: 1341-1362
- Antihypertensive action of β-adrenoceptor blocking drugs.Am J Hypertens. 1989; 2: 237S-240S
- Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life.Circulation. 1994; 90: 762-768
- Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine.J Am Coll Cardiol. 1995; 25: 231-238
- The Total Ischemic Burden European Trial (TIBET).Eur Heart J. 1996; 17: 96-103
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet. 1999; 353: 2001-2017
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.Lancet. 1999; 353: 9-13
- Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.Circulation. 2002; 106: 2194-2199
- β-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials.Arch Intern Med. 2000; 160: 621-627
- The cardiac β-adrenoreceptor–mediated signaling pathway and its alterations in hypertensive heart disease.Hypertension. 1997; 29: 715-722
- The β-blocker heart attack trial.JAMA. 1981; 246: 2073-2074
- Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.N Engl J Med. 1981; 304: 801-807
- β Blockade after myocardial infarction: systematic review and meta regression analysis.BMJ. 1999; 318: 1730-1737
- Electrophysiological properties of intravenous metoprolol in man.Br Heart J. 1978; 40: 650-655
- Optimising the use of β-adrenoceptor antagonists in coronary artery disease.Drugs. 2005; 65: 787-797
- β-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma.Pharmacotherapy. 1999; 19: 974-978
- β-blocker underuse in secondary prevention of myocardial infarction.Ann Pharmacother. 2004; 38: 286-293
- Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.Lancet. 1985; 1: 123-126
- Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?.Am J Hypertens. 1998; 11: 1258-1265
- Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension.Ann Intern Med. 1997; 126: 955-959
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA. 2004; 292: 2227-2236
- Antihypertensive treatment with β-blockers and the spectrum of glycaemic control.QMJ. 2006; 99: 431-436
- Effect of acute selective β-1-adrenoceptor blockade on hormonal and cardiovascular response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.Scand J Clin Lab Invest. 1982; 42: 69-74
- Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the β-Blocker Heart Attack Trial experience.Am J Cardiol. 1990; 65: 1287-1291
- Differentiation of β-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles.Eur Heart J. 1992; 13: 1506-1513
- β-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.J Cardiovasc Pharmacol. 1999; 33: 534-539
- Effects of long-term therapy with laβlol on lipoprotein metabolism in patients with mild hypertension.Acta Med Scand. 1985; 218: 51-54
- β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction.JAMA. 2002; 288: 351-357
- Health issues of men: prevalence and correlates of erectile dysfunction.J Urol. 2005; 174: 662-667
- Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.Drugs. 2005; 65: 773-786
- Patient satisfaction with antihypertensive therapy.J Hum Hypertens. 2005; 19: 793-799
- Nebivolol: a third generation β-adrenergic blocker.Ann Pharmacother. 2006; 40: 1353-1360
- Nebivolol.Cardiol Rev. 2006; 14: 259-264
- Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.J Cardiovasc Pharmacol. 1993; 21: 856-862
- Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination.Am J Hypertens. 1994; 7: 137-145
- Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial.J Human Hypertens. 1998; 12: 135-140
- Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial.J Hum Hypertens. 1997; 11: 813-819
- Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.Blood Press. 2002; 11: 182-188
- Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.Blood Press. 2003; 12: 35-40
- Comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).Cardiovasc Drugs Ther. 2003; 17: 257-263
- Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.Blood Press Suppl. 2003; 1: 30-35
- Quality of life and antihypertensive effect with nebivolol and losartan.Am J Hypertens. 2005; 18: 1060-1066
- Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension.High Blood Press Cardiovasc Prev. 2005; 12: 27-35
- Multiple biomarkers for the prediction of first major cardiovascular events and death.N Engl J Med. 2006; 355: 2631-2639
- A strategy to reduce cardiovascular disease by more than 80%.BMJ. 2003; 326: 14-19
- β blockers in the management of chronic kidney disease.Kidney Int. 2006; 70: 1905-1913
- β blockers in primary hypertension: do age and type of β-blocker matter?.J Hypertens. 2006; 24: 2143-2145
- Present state of alpha- and β-adrenergic drugs I.Am Heart J. 1976; 92: 661-664
- Primary prevention with metoprolol in patients with hypertension.JAMA. 1988; 259: 1976-1982
- Primary prevention of sudden cardiovascular death in hypertensive patients.Am J Hypertens. 1991; 4: 151-158
- Atenolol in hypertension: is it a wise choice?.Lancet. 2004; 364: 1684-1689
- Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).JAMA. 1999; 281: 2005-2012
- Nebivolol reverses endothelial dysfunction in essential hypertension.Circulation. 2001; 104: 511-514
- Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans.Circulation. 2005; 112: 3795-3801
- Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension.J Clin Pharm Ther. 2006; 31: 153-159
- Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).Eur Heart J. 2005; 26: 215-225
- Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity.J Cardiovasc Pharmacol. 2006; 48: 862-869
- Effect of vasodilator therapy on mortality in chronic congestive heart failure.N Engl J Med. 1986; 314: 1547-1552
- Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients.J Hypertens. 2006; 24: 591-596
- Effects of propranolol on atherogenesis in the cholesterol-fed rabbit.Circ Res. 1985; 56: 755-762
- Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS).Arch Intern Med. 1997; 157: 638-648
Article Info
Footnotes
This activity is supported by an educational grant from Forest Pharmaceuticals.
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
